Literature DB >> 19196818

Leptin receptor polymorphisms and lung function decline in COPD.

N N Hansel1, L Gao, N M Rafaels, R A Mathias, E R Neptune, C Tankersley, A V Grant, J Connett, T H Beaty, R A Wise, K C Barnes.   

Abstract

Only a fraction of all smokers develop chronic obstructive pulmonary disease (COPD), suggesting a large role for genetic susceptibility. The leptin receptor (LEPR) is present in human lung tissue and may play a role in COPD pathogenesis. The present study examined the association between genetic variants in the LEPR gene and lung function decline in COPD. In total, 429 European Americans were randomly selected from the National Heart Lung and Blood Institute Lung Health Study. 36 single nucleotide polymorphisms (SNPs) in LEPR were genotyped using the Illumina GoldenGate platform (Broad Institute, Cambridge, MA, USA). Mean annual decline in forced expiratory volume in 1 s % predicted over the 5-yr period was calculated using linear regression. Linear regression models were also used to adjust for potential confounders. In addition, in vivo expression of the receptor gene was assessed with immunohistochemistry on lungs from smoke-exposed inbred mice. We identified significant associations (p<0.05) between lung function decline and 21 SNPs. Haplotype analyses confirmed several of these associations seen with individual markers. Immunohistochemistry results in inbred mice strains support a potential role of LEPR in COPD pathogenesis. We identified genetic variants in the LEPR gene significantly associated with lung function decline in a population of smokers with COPD. Our results support a role for LEPR as a novel candidate gene for COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19196818      PMCID: PMC5516636          DOI: 10.1183/09031936.00120408

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  37 in total

1.  Smoke and mirrors: Mouse models as a reflection of human chronic obstructive pulmonary disease.

Authors:  Steven D Shapiro; Dawn L Demeo; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2004-11-01       Impact factor: 21.405

2.  A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability.

Authors:  N Takabatake; H Nakamura; O Minamihaba; M Inage; S Inoue; S Kagaya; M Yamaki; H Tomoike
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

3.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

4.  Pathophysiological role of leptin in obesity-related hypertension.

Authors:  M Aizawa-Abe; Y Ogawa; H Masuzaki; K Ebihara; N Satoh; H Iwai; N Matsuoka; T Hayashi; K Hosoda; G Inoue; Y Yoshimasa; K Nakao
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

5.  Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers.

Authors:  B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; D S Postma; W Timens
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

6.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.

Authors:  D P Tashkin; M D Altose; J E Connett; R E Kanner; W W Lee; R A Wise
Journal:  Am J Respir Crit Care Med       Date:  1996-06       Impact factor: 21.405

7.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

8.  Hyperleptinemia and reduced TNF-alpha secretion cause resistance of db/db mice to endotoxin.

Authors:  Abram M Madiehe; Tiffany D Mitchell; Ruth B S Harris
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-03       Impact factor: 3.619

9.  Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters.

Authors:  Mukadder Calikoglu; Gulsah Sahin; Ali Unlu; Candan Ozturk; Lülüfer Tamer; Bahadir Ercan; Arzu Kanik; Uğur Atik
Journal:  Respiration       Date:  2004 Jan-Feb       Impact factor: 3.580

10.  Does leptin play a cytokine-like role within the airways of COPD patients?

Authors:  A Bruno; P Chanez; G Chiappara; L Siena; S Giammanco; M Gjomarkaj; G Bonsignore; J Bousquet; A M Vignola
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

View more
  23 in total

Review 1.  Leptin, adiponectin and pulmonary diseases.

Authors:  Nour Ali Assad; Akshay Sood
Journal:  Biochimie       Date:  2012-03-14       Impact factor: 4.079

2.  Pathway-based approaches for sequencing-based genome-wide association studies.

Authors:  Guodong Wu; Degui Zhi
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

Review 3.  Leptin as regulator of pulmonary immune responses: involvement in respiratory diseases.

Authors:  Juanita H J Vernooy; Niki D J Ubags; Guy G Brusselle; Jan Tavernier; Benjamin T Suratt; Guy F Joos; Emiel F M Wouters; Ken R Bracke
Journal:  Pulm Pharmacol Ther       Date:  2013-03-27       Impact factor: 3.410

4.  The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients.

Authors:  Yuliang Li; Jianli Geng; Yongzheng Wang; Qinghua Lu; Yimeng Du; Wujie Wang; Zheng Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-30       Impact factor: 4.553

Review 5.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

Review 6.  Obesity, adipokines, and lung disease.

Authors:  Akshay Sood
Journal:  J Appl Physiol (1985)       Date:  2009-11-19

7.  The methylation of the LEPR/LEPROT genotype at the promoter and body regions influence concentrations of leptin in girls and BMI at age 18 years if their mother smoked during pregnancy.

Authors:  Mitra Yousefi; Wilfried Karmaus; Hongmei Zhang; Susan Ewart; Hasan Arshad; John W Holloway
Journal:  Int J Mol Epidemiol Genet       Date:  2013-06-25

8.  Obesity and asthma: an inflammatory disease of adipose tissue not the airway.

Authors:  Olga Sideleva; Benjamin T Suratt; Kendall E Black; William G Tharp; Richard E Pratley; Patrick Forgione; Oliver Dienz; Charles G Irvin; Anne E Dixon
Journal:  Am J Respir Crit Care Med       Date:  2012-07-26       Impact factor: 21.405

9.  Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD.

Authors:  Nadia N Hansel; Ingo Ruczinski; Nicholas Rafaels; Don D Sin; Denise Daley; Alla Malinina; Lili Huang; Andrew Sandford; Tanda Murray; Yoonhee Kim; Candelaria Vergara; Susan R Heckbert; Bruce M Psaty; Guo Li; W Mark Elliott; Farzian Aminuddin; Josée Dupuis; George T O'Connor; Kimberly Doheny; Alan F Scott; H Marike Boezen; Dirkje S Postma; Joanna Smolonska; Pieter Zanen; Firdaus A Mohamed Hoesein; Harry J de Koning; Ronald G Crystal; Toshiko Tanaka; Luigi Ferrucci; Edwin Silverman; Emily Wan; Jorgen Vestbo; David A Lomas; John Connett; Robert A Wise; Enid R Neptune; Rasika A Mathias; Peter D Paré; Terri H Beaty; Kathleen C Barnes
Journal:  Hum Genet       Date:  2012-09-18       Impact factor: 4.132

10.  Central leptin replacement enhances chemorespiratory responses in leptin-deficient mice independent of changes in body weight.

Authors:  Mirian Bassi; Humberto Giusti; Cristiane Mota Leite; Janete A Anselmo-Franci; Jussara M do Carmo; Alexandre A da Silva; John E Hall; Eduardo Colombari; Mogens L Glass
Journal:  Pflugers Arch       Date:  2012-05-15       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.